Telix to Acquire ANMI for €5.15M

Telix Pharmaceuticals Limited has announced the acquisition of Advanced Nuclear Medicine Ingredients (ANMI) SA for €5.15m in cash and shares.

The acquisition of ANMI significantly expands the market opportunity for Telix’s investment in prostate cancer imaging and builds on the existing commercialization collaboration for the illumetTM prostate imaging (68Ga-PSMA) kit for the US market. Combining the resources, clinical data and human capital of both companies is expected to accelerate the process of preparing a new drug application (NDA) in the United States and Europe for prostate imaging.

Telix chief executive officer Christian Behrenbruch said, "The acquisition of ANMI creates a significantly more capable company with the ability to deliver prostate cancer imaging on a global basis, rather than in a territorially-segmented manner. The clinical availability of prostate cancer imaging will have a major impact on the adoption rate of PSMA radiotherapeutics and therefore this acquisition reinforces our competitive differentiation of offering both imaging and therapy as an integrated solution. We’re very pleased to welcome the talented ANMI team to Telix."

ANMI Co-Founder and chief executive officer Ludovic Wouters said, "ANMI and Telix have achieved a great deal as business partners over the past two years. With the growing importance of nuclear medicine, particularly in urologic oncology, the two companies benefit from establishing an integrated theranostic approach. We also see a clear way for ANMI to contribute to Telix’s product development by packaging their therapeutic products in way that makes them fast and easy to prepare in the radiopharmacy setting."

-----------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.